Cargando…
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine...
Autores principales: | Bénézit, François, Le Bot, Audrey, Jouneau, Stéphane, Lemaître, Florian, Pronier, Charlotte, Lentz, Pierre-Axel, Patrat-Delon, Solène, Revest, Matthieu, Thibault, Vincent, Tattevin, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510728/ https://www.ncbi.nlm.nih.gov/pubmed/32609083 http://dx.doi.org/10.3201/eid2610.201816 |
Ejemplares similares
-
Prevalence and characteristics of persistent symptoms after non-severe COVID-19: a prospective cohort study
por: Armange, Lucas, et al.
Publicado: (2021) -
Prévalence et mécanismes des symptômes persistants invalidants à six semaines d’une infection à SARS-Cov2
por: Armange, L., et al.
Publicado: (2020) -
Histoire naturelle de la COVID-19 avec suivi prospectif systématique standardisé : combien de temps durent les symptômes ?
por: Bénézit, F., et al.
Publicado: (2020) -
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19
por: Bénézit, François, et al.
Publicado: (2020) -
No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on “Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France”
por: Lebeaux, David, et al.
Publicado: (2020)